Karyopharm Therapeutics(KPTI) - 2024 Q2 - Quarterly Results

Exhibit 99.1 1 BELIEVERS IN THE EXTRAORDINARY Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress – Achieves Second Quarter 2024 Total Revenue of $42.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.0 Million; Positive Momentum ex-US with Continued Regulatory and Reimbursement Approvals – – Updated Clinical Results at ASCO Annual Meeting Showed Median Progression-Free Survival (PFS) of 28.4 Months in the TP53 Wild-Type Exploratory Subgroup and 39. ...